Literature DB >> 29600319

Patients with unilateral squamous cell carcinoma of the tongue and ipsilateral lymph node metastasis do not profit from bilateral neck dissection.

Christoph Klingelhöffer1, Andreas Gründlinger2, Gerrit Spanier2, Stephan Schreml3, Maximilian Gottsauner2, Steffen Mueller2, Johannes K Meier2, Torsten E Reichert2, Tobias Ettl2.   

Abstract

OBJECTIVES: The purpose of this study was to evaluate the necessity of elective bilateral neck dissection for treating strict unilateral squamous cell carcinoma (SCC) of the tongue.
METHODS: A cohort of 169 patients with unilateral non-midline crossing SCCs of the tongue treated by local resection and neck dissection was investigated. Study endpoints were nodal relapse and overall survival. The mean follow-up was 7.4 years.
RESULTS: A total of 146 (88.1%) patients were treated by neck dissection. Lymph node metastases were diagnosed in 50 (34.2%) patients. Only two (1.1%) had contralateral lymph node metastases. Risk factors for developing a primary lymph node metastasis were size of tumor (T2/T3, p = 0.03; OR = 2.2), lymphangiosis (p = 0.003; OR = 4.7), and higher-grade differentiation (p = 0.051; OR = 2.43). Metachronous lymph node metastases were detected in 23 (13.6%) patients (19 ipsilateral, one contralateral and three bilateral). The main risk factor for developing a metachronous lymph node metastasis was the presence of a primary lymph node metastasis (p = 0.004; HR = 4.65). Patients with initial neck dissection came up with lower 5-year recurrence rates (13.6%) compared to patients without neck dissection (27.3%; p = 0.014). Bilateral neck dissection showed no advantage regarding nodal relapse free and overall survival (p = 0.606) compared to unilateral neck dissection irrespective of initial N or T stage.
CONCLUSION: Patients with unilateral SCC of the tongue benefit from an ipsilateral neck dissection regarding nodal relapse. The value of elective bilateral neck dissection as standard treatment seems questionable even if positive lymph nodes were diagnosed ipsilateral at primary therapy.

Entities:  

Keywords:  Bilateral; Elective neck dissection; Head and neck cancer; Ipsilateral; Oral cancer; Oral tongue squamous cell carcinoma

Mesh:

Year:  2018        PMID: 29600319     DOI: 10.1007/s10006-018-0690-1

Source DB:  PubMed          Journal:  Oral Maxillofac Surg        ISSN: 1865-1550


  33 in total

1.  Level IIb lymph nodes metastasis in elective supraomohyoid neck dissection for oral cavity squamous cell carcinoma: a molecular-based study.

Authors:  Mohamed Nasser Elsheikh; Magdy Elsayed Mahfouz; Ehab Elsheikh
Journal:  Laryngoscope       Date:  2005-09       Impact factor: 3.325

2.  Elective neck dissection in unilateral carcinomas of the tongue: Unilateral versus bilateral approach.

Authors:  Christopher-Philipp Nobis; Sven Otto; Tamara Grigorieva; Mohamed Alnaqbi; Matthias Troeltzsch; Jakob Schöpe; Stefan Wagenpfeil; Michael Ehrenfeld; Klaus-Dietrich Wolff; Marco Rainer Kesting
Journal:  J Craniomaxillofac Surg       Date:  2017-01-25       Impact factor: 2.078

3.  Quality of life after neck dissection.

Authors:  Hiroyuki Inoue; Ken-Ichi Nibu; Miki Saito; Naoki Otsuki; Haruhiko Ishida; Tetsuro Onitsuka; Takashi Fujii; Kazuyoshi Kawabata; Masahisa Saikawa
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2006-06

4.  Improved survival for patients with clinically T1/T2, N0 tongue tumors undergoing a prophylactic neck dissection.

Authors:  K J Haddadin; D S Soutar; R J Oliver; M H Webster; A G Robertson; D G MacDonald
Journal:  Head Neck       Date:  1999-09       Impact factor: 3.147

5.  Neck dissection versus "watchful-waiting" in early squamous cell carcinoma of the tongue our experience on 127 cases.

Authors:  Giovanni Dell'Aversana Orabona; Paola Bonavolontà; Fabio Maglitto; Marco Friscia; Giorgio Iaconetta; Luigi Califano
Journal:  Surg Oncol       Date:  2016-09-21       Impact factor: 3.279

Review 6.  Metastasis of squamous cell carcinoma of the oral tongue.

Authors:  Daisuke Sano; Jeffrey N Myers
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

7.  Preserving level IIb lymph nodes in elective supraomohyoid neck dissection for oral cavity squamous cell carcinoma.

Authors:  Young Chang Lim; Mee Hyun Song; Sang Cheol Kim; Kwang Moon Kim; Eun Chang Choi
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2004-09

8.  Treatment of contralateral N0 neck in early squamous cell carcinoma of the oral tongue: elective neck dissection versus observation.

Authors:  Young Chang Lim; Jin Seok Lee; Bon Seok Koo; Se-Heon Kim; Young-Ho Kim; Eun Chang Choi
Journal:  Laryngoscope       Date:  2006-03       Impact factor: 3.325

9.  Unilateral, clinically T2N0, squamous cell carcinoma of the tongue: surgical outcome analysis.

Authors:  Y C Lim; E C Choi
Journal:  Int J Oral Maxillofac Surg       Date:  2007-03-06       Impact factor: 2.789

10.  Prediction of Lymph Node Metastasis by Tumor Dimension Versus Tumor Biological Properties in Head and Neck Squamous Cell Carcinomas.

Authors:  Jeon Yeob Jang; Min Ji Kim; Gwanghui Ryu; Nayeon Choi; Young-Hyeh Ko; Han-Sin Jeong
Journal:  Cancer Res Treat       Date:  2015-03-06       Impact factor: 4.679

View more
  2 in total

1.  Contralateral Regional Recurrence in Lateralized or Paramedian Early-Stage Oral Cancer Undergoing Sentinel Lymph Node Biopsy-Comparison to a Historic Elective Neck Dissection Cohort.

Authors:  Rutger Mahieu; Inne J den Toom; Koos Boeve; Daphne Lobeek; Elisabeth Bloemena; Maarten L Donswijk; Bart de Keizer; W Martin C Klop; C René Leemans; Stefan M Willems; Robert P Takes; Max J H Witjes; Remco de Bree
Journal:  Front Oncol       Date:  2021-04-23       Impact factor: 6.244

2.  Treatment and Prognosis of Oral Cancer Patients with Confirmed Contralateral Neck Metastasis: A Multicenter Retrospective Analysis.

Authors:  Yuki Sakamoto; Mitsunobu Otsuru; Takumi Hasegawa; Masaya Akashi; Shin-Ichi Yamada; Hiroshi Kurita; Masaya Okura; Nobuhiro Yamakawa; Tadaaki Kirita; Souichi Yanamoto; Masahiro Umeda; Yuka Kojima
Journal:  Int J Environ Res Public Health       Date:  2022-07-28       Impact factor: 4.614

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.